Claims for Patent: 7,541,328

Summary for Patent: 7,541,328

Title:	Coupling proteins to a modified polysaccharide
Abstract:	The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.
Inventor(s):	Hemberger; Jurgen (Aschaffenburg, DE), Orlando; Michele (The Hague, NL), Sommermeyer; Klaus (Rosbach v.d.H, DE), Eichner; Wolfram (Butzbach, DE), Frie; Sven (Bramois, CH), Lutterbeck; Katharina (Friedberg, DE), Jungheinrich; Cornelius (Bad Homburg, DE), Scharpf; Roland (Ranstadt, DE)
Assignee:	Fresenius Kabi Deutschland GmbH (Bad Homburg v.d.H, DE)
Application Number:	10/506,367
Patent Claims:	1. A hydroxyethylstarch-protein conjugate, characterized in that the binding interaction between the hydroxyethylstarch molecule and the protein is a single covalent bonding which is the result of a coupling reaction between (i) the terminal aldehyde group of the hydroxyethylstarch molecule and (ii) a primary amino group of the protein to form a Schiff's base. 2. The conjugate as claimed in claim 1, characterized in that the covalent bonding is an amine linkage which is the result of a reduction of the Schiff's base to the amine. 3. The conjugate as claimed in claim 1, characterized in that the hydroxyethylstarch molecule has a molecular weight in the range from about 4 to about 1000 kDa. 4. The conjugate as claimed in claim 3, characterized in that the hydroxyethylstarch molecule has a molecular weight of about 4 to about 50 kDa. 5. The conjugate as claimed in claim 3, characterized in that the hydroxyethylstarch molecule has a molecular weight of about 70 to about 1000 kDa. 6. The conjugate as claimed in claim 5, characterized in that the hydroxyethylstarch molecule has a molecular weight of about 130 kDa. 7. The conjugate as claimed in claim 1, characterized in that the hydroxyethylstarch molecule has a degree of substitution of about 0.3 to about 0.7. 8. The conjugate as claimed in claim 1, characterized in that the hydroxyethylstarch molecule has a ratio of C.sub.2 to C.sub.6 substitution of from 8 to 12. 9. The conjugate as claimed in claim 1, characterized in that the protein has a regulatory or catalytic function, a signal transmitting or transport function or a function in the immune response or induction of an immune response. 10. The conjugate as claimed in claim 9, characterized in that the protein is selected from the group consisting of enzymes, antibodies, antigens, transport proteins, bioadhesion proteins, hormones and prohormones, growth factors and growth factor receptors, cytokines, receptors, suppressors, activators, and inhibitors. 11. The conjugate as claimed in claim 9, characterized in that the protein is .alpha.-, .beta.- or .gamma.-interferon, an interleukin, a serum protein, erythropoietin, myoglobin, hemoglobin, a plasminogen activator, BCGF, BDGF, EGF, FGF, NGF, PDGF, BDNF, CNTF, TGF-.alpha., TGF-.beta., a colony-stimulating factor, a BMP, somatomedin, somatotropin, somatostatin, insulin, gonadotropin, .alpha.-MSH, triptorelin, prolactin, calcitonin, glucagon, a glucagon-like peptide, exendin, leptin, gastrin, secretin, an integrmn, a hypothalamus hormone, a thyroid hormone, a growth hormone, LH, FSH, a pigmentary hormone, TNF-.alpha. or TNF-.beta., hirudin, a lipoprotein or apolipoprotein, an oligolysine protein, an RGD protein, a lectin or ricin, bee venom or a snake venom, an immunotoxin, ragweed allergen, antigen E, an immunoglobulin, or a receptor for one of these proteins. 12. The conjugate as claimed in claim 9, characterized in that the protein is an enzyme which is selected from the group consisting of an asparaginase, arginase, arginine deaminase, adenosine deaminase, glutaminase, glutaminase-asparaginase, phenylalanine ammonia-lyase, tryptophanase, tyrosinase, superoxide dismutase, endotoxinase, catalase, peroxidase, kallikrein, trypsin, chymotrypsin, elastase, thermolysin, a lipase, unease, adenosine diphosphatase, purine-nucleoside phosphorylase, bilirubin oxidase, glucose oxidase, glucodase, gluconate oxidase, galactosidase, glucocerebrosidase, glucuronidase, hyaluronidase, tissue factor, a tissue plasminogen activator, streptokinase, urokinase, an MAP kinase, DNAse, RNAse, and lactoferrin. 13. A pharmaceutical composition comprising an effective amount of a conjugate as claimed in claim 1 and a pharmaceutically acceptable carrier and, where appropriate, further excipients and active ingredients. 14. A method for preparing a hydroxyethvlstarch-protein conjugate in which the binding interaction between the hydroxyethylstarch molecule and the protein is a single covalent bonding which is the result of a coupling reaction between (i) the terminal aldehyde group of the hydroxyethylstarch molecule and (ii) a primary amino group of the protein to form a Schiff's base, characterized in that the coupling reaction is carried out in aqueous solution between the terminal aldehyde group of the hydroxyethylstarch molecule and a primary amino group of the protein. 15. The method as claimed in claim 14, characterized in that the reaction medium of the coupling reaction is water or a mixture of water and an organic solvent, where the water content of the mixture is at least 80%. 16. The method as claimed in claim 14, characterized in that the terminal aldehyde group of the hydroxyethylstarch molecule is coupled to a primary amino group of the protein to form a Schiff's base, and the formed Schiff's base is reduced to the amine, so that the hydroxyethylstarch molecule is linked to the protein by an amine linkage. 17. The method as claimed in claim 16, characterized in that both coupling and reduction take place in aqueous solution. 18. The method as claimed in claim 16, characterized in that the reducing agent is sodium borohydride, sodium cyanoborohydride or an organic boron complex. 19. The method as claimed in claim 16, characterized in that the coupling and reduction reactions are carried out simultaneously.

Details for Patent 7,541,328

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2022-03-06
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2022-03-06
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2022-03-06
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2022-03-06
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2022-03-06